Literature DB >> 28029519

Adrenocorticotropic hormone levels before treatment predict recurrence of Cushing's disease.

Chun-Heng Kuo1, Shyang-Rong Shih2, Hung-Yuan Li3, Szu-Chi Chen1, Po-Ju Hung4, Fen-Yu Tseng5, Tien-Chun Chang6.   

Abstract

BACKGROUND/
PURPOSE: Cushing's disease (CD) is the most common cause of endogenous Cushing's syndrome. Transsphenoidal surgery (TSS) is the first choice of treatment. Predicting prognosis after treatment can benefit further strategies of management, but currently there is no convenient predictor. This study aims to investigate characteristic changes after treatment and to identify potential prognostic predictors.
METHODS: We retrospectively studied the records of CD patients presenting to the National Taiwan University Hospital, Taipei, Taiwan between 1992 and 2011. They were categorized according to treatment response. Clinical features and examination findings were compared between groups.
RESULTS: Forty-one patients with CD were included. The follow-up time was 0.26-19.3 years. The time interval between the onset of symptoms and diagnosis was 2.1-120.0 months. The initial remission rate of CD after the first treatment was 82.9%. Mean body mass index (BMI) was 27.4 kg/m2 before treatment and 26.0 kg/m2 3 months after treatment. The patients in remission had a greater decrease in BMI after treatment and lower dehydroepiandrosterone sulfate (DHEAS) levels before treatment, compared with the recurrent group (both p < 0.05). Adrenocorticotropic hormone (ACTH) levels before treatment showed a significant positive correlation with recurrent diseases (p < 0.05).
CONCLUSION: A larger decrease in BMI after treatment and lower DHEAS levels before treatment were noted for the patients who stayed in CD remission. Higher ACTH levels before treatment predicted a recurrence of CD. These are potentially simple and practical predictors of prognosis.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Cushing's disease; body mass index; dehydroepiandrosterone sulfate; recurrence

Mesh:

Substances:

Year:  2016        PMID: 28029519     DOI: 10.1016/j.jfma.2016.08.008

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

1.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

Review 2.  The experience with transsphenoidal surgery and its importance to outcomes.

Authors:  Jürgen Honegger; Florian Grimm
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 3.  Treatment challenges in pediatric Cushing's disease: Review of the literature with particular emphasis on predictive factors for the disease recurrence.

Authors:  Katarzyna Pasternak-Pietrzak; Elżbieta Moszczyńska; Mieczysław Szalecki
Journal:  Endocrine       Date:  2019-11-07       Impact factor: 3.633

4.  The Utility of Preoperative ACTH/Cortisol Ratio for the Diagnosis and Prognosis of Cushing's Disease.

Authors:  Alev Selek; Berrin Cetinarslan; Zeynep Canturk; Ilhan Tarkun; Ozlem Zeynep Akyay; Burak Cabuk; Savas Ceylan
Journal:  J Neurosci Rural Pract       Date:  2018 Jan-Mar

Review 5.  Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment.

Authors:  Leah T Braun; German Rubinstein; Stephanie Zopp; Frederick Vogel; Christine Schmid-Tannwald; Montserrat Pazos Escudero; Jürgen Honegger; Roland Ladurner; Martin Reincke
Journal:  Endocrine       Date:  2020-08-02       Impact factor: 3.633

Review 6.  Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge.

Authors:  José Miguel Hinojosa-Amaya; Elena V Varlamov; Shirley McCartney; Maria Fleseriu
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-08       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.